echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Deki Pharmaceuticals Selinexor's three treatments were selected for the latest edition of NCCN Guidelines ®

    Deki Pharmaceuticals Selinexor's three treatments were selected for the latest edition of NCCN Guidelines ®

    • Last Update: 2020-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 15th Deki Pharmaceuticals Limited ("Deki Pharmaceuticals") announced that the National Comprehensive Cancer Network (NCCN®) had added three selinexor (ATG-010) to the latest edition of the Clinical Practice Guide for Multiple Myeloma (NCCN Guidelines®) for the treatment of patients with recurring multiple myeloma (rrMM). The combined solutions are: SVd schemes based on BOSTON research support (selinexor-boronitzomi-desemisson), SDd schemes supported by STOMP studies (selinexor-daretoyu monoanti-desamisson) and SPD solutions (selinexor-pomadamine-desamisson), wherein SPd is a full-oral treatment.
    this NCCN® guideline update only covers the update of the selinexor content, and it is worth noting that the SVd option has become a category 1 recommendation of the guide, which also indicates that the treatment option with selinexor as the skeleton will provide MM patients with new treatment options.
    multiple myeloma is a malignant disease of abnormal proliferation of cloned plasma cells, and in many countries it is the second most common malignant tumor in the blood system1.
    rrMM is still incurable and prone to recurrence, and there is a lack of standard treatment options after recurrence.
    more and more new drugs are being used in the clinic, how to choose the right treatment is also a clinical challenge.
    NCCN® guidelines will provide important guidance for the treatment of rrMM patients, and hematologists at home and abroad are also very concerned about the update of the guidelines, and the selinexor into the new version of the NCCN® guidelines are highly rated.
    "Recently, the NCCN® multiple myeloma guidelines were updated to the fourth edition of 2021, and several options for selinexor have been included in the latest version of the recommendation guidelines," said Professor Qiu Yugui of the Hospital of Hematology of the Chinese Academy of Medical Sciences.
    , selinexor's weekly programmes (SVds) of co-boron tyzomi and dexamisong have been included in the recommendations of a class of programmes for patients with relapsed rrMM.
    the efficacy and safety of SVd in patients with relapsed rrMM who have previously received 1-3-line treatment published in LANCET2 this year, the study data are encouraging.
    is conducting a joint Phase II clinical trial in China, where the effectiveness and safety of the program is similar to that of registered clinical trials in the United States, and there are no new safety incidents.
    with our growing understanding of the selinexor joint solution and the growing experience in clinical applications, we believe that selinexor will give rrMM patients more hope for survival.
    , Professor Fu Weijun of Shanghai Long March Hospital, said: "On December 10th, NCCN®'s latest MM guidelines added treatment options, providing more options for the treatment of rrMM patients.
    , we also saw a familiar drug, celinexor, which was recently presented at a major conference in the field of hematoma.
    from previously published data, SVd treatment of patients with rrMM who had relapsed after 1-3 lines of treatment had a total efficiency (ORR) of 76%, and SPd treatment of rrMM patients with multiple recurrences, ORR was close to 60%, with significant efficacy.
    addition, selinexor combined with the Dretoyu monoantitherapy treatment program can improve the overall efficacy.
    study ad fittingly illustrates that celinexor, as a drug with a new mechanism of action, can be effectively combined with existing drugs to further improve efficacy and prolong patients' progression-free life.
    I hope to see more clinical data in Chinese patients in the future, and to benefit more MM patients based on its outstanding efficacy as early as possible in the China recommendation guidelines. Dr. Jianming Mei, Founder, Chairman and CEO of
    " Deki Pharmaceuticals, said, "Selinexor's recommendation guidelines for entering NCCN® are based on the significant efficacy of the product in treating recurring recurring refractory multiple myeloma;
    It is an honor to see Selinexor recognized by professionals and professional associations, and we will continue to explore the clinical potential of this drug to maximize the benefits to patients in China, Asia Pacific and around the world."
    NCCN® guidelines are currently the best treatment guidelines for medical professionals around the world, and the entry of three different selinexor combinations further validates the importance of selinexor in future treatment of multiple myeloma.
    About Selinexor (ATG-010, XPOVIO® Selinexor (ATG-010, XPOVIO®) is the first and only oral selective nuclear output inhibitor (SINE) compound of its kind, developed by Deki Pharmaceuticals in collaboration with Karyopharm Therapeutics Inc.
    July 2019, the U.S. Food and Drug Administration (FDA) approved selinexor combined with low-dose dexamisong for the treatment of patients with recurring multiple myeloma (rrMM).
    June 2020, the FDA again approved selinexor as a single-drug oral therapy for the treatment of patients with recurring refractic, incurable large B-cell lymphoma (rrDLBCL).
    is the first and only oral SINE compound approved by the FDA.
    , Selinexor conducted a number of mid- and post-clinical trials for multiple solid tumor adaptations, including liposarcoma and endometrial cancer.
    In November 2020, Deki Pharmaceutical Partner Karyopharm reported positive data from the Phase III SEAL study, a randomized, double-blind, placebo-controlled cross-study designed to compare the efficacy of oral monodripose selinexor with placebo in patients with liposarcoma, at the 2020 Annual Meeting of connective tissue oncology (CTOS 2020).
    Karyopharm recently published the Phase III SIENDO study for the treatment of endometrial cancer patients, which has passed a planned medium-term ineffectiveness analysis.
    , the Data Security Monitoring Board (DSMB) recommended that the SIENDO study proceed without any modifications as planned, and the top-line data for the SIENDO trial is expected to be released in the second half of 2021.
    Deqi Pharmaceuticals is conducting a Phase II registered clinical study (code-named MARCH) on recurring multiple myeloma in China, as well as a phase II registered clinical study (code-named SEARCH) on recurring diffuseric large B-cell lymphoma.
    at the same time, Deki Pharmaceuticals initiated clinical studies (code-named TRUMP) for the treatment of external T-cell lymphoma, NK/T-cell lymphoma (code-named TOUCH) and KRAS mutated non-small cell lung cancer for Asia Pacific high-risk tumors.
    original title: New advances in myeloma treatment, new mechanism of action drug Selinexor (ATG-010) three treatment options were selected in the latest edition of NCCN® multiple myeloma diagnosis and treatment guidelines
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.